The sphingolipid metabolism pathway proves indispensable in the metastatic process of lung cancer (Pyne et al., 2018; Coant and Hannun, 2019); its potential as a novel therapeutic target holds significant promise for augmenting the efficacy of tumor treatments (Vijayan et al., 2019), and animal experiments have demonstrated that NPC1L1 inhibition can modulate sphingolipid metabolism (Yamanashi et al., 2020). Here, NPC1L1 is linked to lung carcinoma.